Endocrine Oncology Unit, Instituto Nacional de Cancerología, Bogotá Colombia, Colombia; CES - Universidad del Rosario Epidemiology Magister, Bogotá Colombia, Colombia.
Clinical and Epidemiological Cancer Research Unit, Instituto Nacional de Cancerología, Bogotá Colombia, Colombia.
Ann Endocrinol (Paris). 2020 Dec;81(6):539-544. doi: 10.1016/j.ando.2020.11.005. Epub 2020 Dec 5.
Second primary neoplasms are associated with high mortality and morbidity rates in cancer survivors successfully treated for the first malignancy. Studies suggested an association between the type of first neoplasm and risk of subsequent thyroid cancer, with part of this risk attributable to exposure to radiotherapy during treatment of the first primary tumor. This study aimed to determine whether radiotherapy is a risk factor for thyroid cancer in patients previously treated for another neoplasm.
This retrospective case-control study included patients diagnosed with their first cancer between 2007 and 2017. Patients who subsequently developed thyroid cancer as a second primary neoplasm were defined as "cases", and patients who did not develop a second cancer were defined as "controls". Exposure to radiotherapy was the primary risk factor of interest; other risk factors were the site to which radiotherapy was delivered and the first neoplasm type.
Exposure to radiotherapy was associated with an increased risk of thyroid cancer (odds ratio [OR]=2.410, 95% confidence interval [CI]: 1.219-4.764), in particular, in women (OR=3.121, 95% CI: 1.232-7.907) and in patients receiving radiotherapy to the thorax (OR=6.298, 95% CI: 2.581-15.370). The median survival time from first cancer recovery to thyroid cancer occurrence was 63.80 months; there was no difference in survival between patients who did and did not receive radiotherapy (P=0.899).
Radiation to the thorax can increase the risk of thyroid cancer as a second neoplasm among patients with cancer successfully treated for their first cancer.
对于成功治疗首次恶性肿瘤的癌症幸存者,第二原发肿瘤与高死亡率和发病率相关。有研究表明,首次肿瘤的类型与随后发生甲状腺癌的风险之间存在关联,其中部分风险归因于首次原发性肿瘤治疗期间接受的放射治疗。本研究旨在确定放射治疗是否是先前治疗过另一种肿瘤的患者发生甲状腺癌的危险因素。
这是一项回顾性病例对照研究,纳入了 2007 年至 2017 年间诊断出患有首次癌症的患者。随后被诊断为第二原发甲状腺癌的患者被定义为“病例”,未发生第二癌症的患者被定义为“对照”。放射治疗暴露是主要的感兴趣的危险因素;其他危险因素包括放射治疗部位和首次肿瘤类型。
放射治疗暴露与甲状腺癌风险增加相关(比值比 [OR]=2.410,95%置信区间 [CI]:1.219-4.764),尤其是在女性(OR=3.121,95% CI:1.232-7.907)和接受胸部放射治疗的患者中(OR=6.298,95% CI:2.581-15.370)。从首次癌症康复到甲状腺癌发生的中位生存时间为 63.80 个月;接受和未接受放射治疗的患者之间的生存无差异(P=0.899)。
对于成功治疗首次癌症的癌症幸存者,胸部放射治疗可增加第二原发甲状腺癌的风险。